SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
04 2021
Historique:
received: 03 11 2020
revised: 13 01 2021
accepted: 15 01 2021
pubmed: 12 2 2021
medline: 7 4 2021
entrez: 11 2 2021
Statut: ppublish

Résumé

The extent to which very young children contribute to the transmission of SARS-CoV-2 is unclear. We aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 in daycare centres that remained open for key workers' children during a nationwide lockdown in France. Children and staff who attended one of 22 daycare centres during a nationwide lockdown in France (between March 15 and May 9, 2020) were included in this cross-sectional, multicentre, seroprevalence study. Hospital staff not occupationally exposed to patients with COVID-19, or to children, were enrolled in a comparator group. The primary outcome was SARS-CoV-2 seroprevalence in children, daycare centre staff, and the comparator group. The presence of antibodies against SARS-CoV-2 in capillary whole blood was measured with a rapid chromatographic immunoassay. We computed raw prevalence as the percentage of individuals with a positive IgG or IgM test, and used Bayesian smoothing to account for imperfect sensitivity and specificity of the assay. This study is registered with ClinicalTrials.gov, NCT04413968. Between June 4 and July 3, 2020, we enrolled 327 children (mean age 1·9 [SD 0·9] years; range 5 months to 4·4 years), 197 daycare centre staff (mean age 40 [12] years), and 164 adults in the comparator group (42 [12] years). Positive serological tests were observed for 14 children (raw seroprevalence 4·3%; 95% CI 2·6-7·1) and 14 daycare centre staff (7·7%; 4·2-11·6). After accounting for imperfect sensitivity and specificity of the assay, we estimated that 3·7% (95% credible interval [95% CrI] 1·3-6·8) of the children and 6·8% (3·2-11·5) of daycare centre staff had SARS-CoV-2 infection. The comparator group fared similarly to the daycare centre staff; nine participants had a positive serological test (raw seroprevalence 5·5%; 95% CI 2·9-10·1), leading to a seroprevalence of 5·0% (95% CrI 1·6-9·8) after accounting for assay characteristics. An exploratory analysis suggested that seropositive children were more likely than seronegative children to have been exposed to an adult household member with laboratory-confirmed COVID-19 (six [43%] of 14 vs 19 [6%] of 307; relative risk 7·1 [95% CI 2·2-22·4]). According to serological test results, the proportion of young children in our sample with SARS-CoV-2 infection was low. Intrafamily transmission seemed more plausible than transmission within daycare centres. Further epidemiological studies are needed to confirm this exploratory hypothesis. Assistance Publique-Hôpitaux de Paris; Mairie de Paris, Conseil Départemental de Seine Saint Denis. For the French translation of the abstract see Supplementary Materials section.

Sections du résumé

BACKGROUND
The extent to which very young children contribute to the transmission of SARS-CoV-2 is unclear. We aimed to estimate the seroprevalence of antibodies against SARS-CoV-2 in daycare centres that remained open for key workers' children during a nationwide lockdown in France.
METHODS
Children and staff who attended one of 22 daycare centres during a nationwide lockdown in France (between March 15 and May 9, 2020) were included in this cross-sectional, multicentre, seroprevalence study. Hospital staff not occupationally exposed to patients with COVID-19, or to children, were enrolled in a comparator group. The primary outcome was SARS-CoV-2 seroprevalence in children, daycare centre staff, and the comparator group. The presence of antibodies against SARS-CoV-2 in capillary whole blood was measured with a rapid chromatographic immunoassay. We computed raw prevalence as the percentage of individuals with a positive IgG or IgM test, and used Bayesian smoothing to account for imperfect sensitivity and specificity of the assay. This study is registered with ClinicalTrials.gov, NCT04413968.
FINDINGS
Between June 4 and July 3, 2020, we enrolled 327 children (mean age 1·9 [SD 0·9] years; range 5 months to 4·4 years), 197 daycare centre staff (mean age 40 [12] years), and 164 adults in the comparator group (42 [12] years). Positive serological tests were observed for 14 children (raw seroprevalence 4·3%; 95% CI 2·6-7·1) and 14 daycare centre staff (7·7%; 4·2-11·6). After accounting for imperfect sensitivity and specificity of the assay, we estimated that 3·7% (95% credible interval [95% CrI] 1·3-6·8) of the children and 6·8% (3·2-11·5) of daycare centre staff had SARS-CoV-2 infection. The comparator group fared similarly to the daycare centre staff; nine participants had a positive serological test (raw seroprevalence 5·5%; 95% CI 2·9-10·1), leading to a seroprevalence of 5·0% (95% CrI 1·6-9·8) after accounting for assay characteristics. An exploratory analysis suggested that seropositive children were more likely than seronegative children to have been exposed to an adult household member with laboratory-confirmed COVID-19 (six [43%] of 14 vs 19 [6%] of 307; relative risk 7·1 [95% CI 2·2-22·4]).
INTERPRETATION
According to serological test results, the proportion of young children in our sample with SARS-CoV-2 infection was low. Intrafamily transmission seemed more plausible than transmission within daycare centres. Further epidemiological studies are needed to confirm this exploratory hypothesis.
FUNDING
Assistance Publique-Hôpitaux de Paris; Mairie de Paris, Conseil Départemental de Seine Saint Denis.
TRANSLATIONS
For the French translation of the abstract see Supplementary Materials section.

Identifiants

pubmed: 33571450
pii: S2352-4642(21)00024-9
doi: 10.1016/S2352-4642(21)00024-9
pmc: PMC9180428
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0

Banques de données

ClinicalTrials.gov
['NCT04413968']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

256-264

Investigateurs

Lorelei Charbonnier (L)
Anais Chosidow (A)
Véronique Hentgen (V)
Oscar Lescano (O)
Nathalie Mestre (N)
Gaelle Pinto Cardoso (G)
Roselyne Masson (R)
Bahia Rabehi (B)
Anne-Sophie Romain (AS)
François Vié le Sage (F)
Xavier Vuillaume (X)

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
BMC Infect Dis. 2014 Dec 11;14:670
pubmed: 25495228
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
N Engl J Med. 2020 Jul 9;383(2):187-190
pubmed: 32356945
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1100-1101
pubmed: 32790658
Pediatrics. 2020 Aug;146(2):
pubmed: 32457212
Pediatr Infect Dis J. 2020 Aug;39(8):e202-e204
pubmed: 32496407
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Pediatrics. 2020 Jul;146(1):
pubmed: 32376725
Clin Infect Dis. 2020 Jul 28;71(15):825-832
pubmed: 32277759
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Eur J Pediatr. 2020 Jul;179(7):1029-1046
pubmed: 32424745
BMJ Open. 2013 Feb 26;3(2):
pubmed: 23447463
Emerg Infect Dis. 2021 Feb;27(2):636-638
pubmed: 33349310
Nat Commun. 2021 May 21;12(1):3025
pubmed: 34021152
Pediatrics. 2021 Jan;147(1):
pubmed: 33055228
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Lancet Child Adolesc Health. 2020 Nov;4(11):807-816
pubmed: 32758454
Lancet Infect Dis. 2020 Jun;20(6):689-696
pubmed: 32220650
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Lancet Child Adolesc Health. 2020 Sep;4(9):653-661
pubmed: 32593339
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398
pubmed: 32979314
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613

Auteurs

Eric Lachassinne (E)

Université Paris 13, Sorbonne Paris cité, AP-HP, Hôpital Jean Verdier, Service de Pédiatrie, Bondy, France.

Loïc de Pontual (L)

Université Paris 13, Sorbonne Paris cité, AP-HP, Hôpital Jean Verdier, Service de Pédiatrie, Bondy, France.

Marion Caseris (M)

AP-HP, Hôpital Robert Debré, Service de Pédiatrie générale, Paris, France.

Mathie Lorrot (M)

Sorbonne Université, AP-HP, Hôpital Armand Trousseau, Service de Pédiatrie, Paris, France; Inserm, U1123, ECEVE, Paris, France.

Carole Guilluy (C)

Université de Paris, AP-HP, Hôpital Louis Mourier, Service de Pédiatrie-Urgences, Colombes, France.

Aurélie Naud (A)

Service de Pédiatrie, Hôpital Annecy Genevois, Annecy, France.

Marie-Aliette Dommergues (MA)

Service de Pédiatrie, Hôpital André Mignot, Versailles, France.

Didier Pinquier (D)

Service de Pédiatrie Néonatale et Réanimation, CHU de Rouen, Rouen, France.

Evelyne Wannepain (E)

Service de la Protection Maternelle et Infantile, Conseil Départemental de Seine Saint Denis, Bobigny, France.

Elisabeth Hausherr (E)

Service de la Protection Maternelle et Infantile, Ville de Paris, Paris, France.

Camille Jung (C)

Centre de recherche clinique-centre de Ressources biologiques, CHI Créteil, Créteil, France; Service de pédiatrie Générale, CHI Créteil, Créteil, France.

Vincent Gajdos (V)

Université Paris-Saclay, AP-HP, Hôpital Antoine Béclère, Service de Pédiatrie, Clamart, France.

Robert Cohen (R)

Groupe de Pathologies infectieuses, Association clinique et thérapeutique infantile du Val-de-Marne, ACTIV, Saint-Maur-des- Fossés, France.

Jean-Ralph Zahar (JR)

Université Paris 13, Sorbonne Paris cité, AP-HP, Hôpital Avicenne, Unité de Prévention du Risque Infectieux, Laboratoire de Microbiologie Clinique, Bobigny, France.

Ségolène Brichler (S)

Université Paris 13, Sorbonne Paris cité, AP-HP, Hôpital Avicenne, Laboratoire de virologie, Bobigny, France.

Romain Basmaci (R)

Université de Paris, AP-HP, Hôpital Louis Mourier, Service de Pédiatrie-Urgences, Colombes, France.

Pierre-Yves Boelle (PY)

Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Paris, France.

Coralie Bloch-Queyrat (C)

Université Paris 13, Sorbonne Paris cité, INSERM U1163/CNRS ERL 8254, AP-HP, Hôpital Avicenne, URC-CRC GHPSS, Bobigny, France.

Camille Aupiais (C)

Université Paris 13, Sorbonne Paris cité, AP-HP, Hôpital Jean Verdier, Service de Pédiatrie, Bondy, France; Inserm, U1138, Équipe 22, Centre de Recherche des Cordeliers, Sorbonne Université, Paris, France. Electronic address: camille.aupiais@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH